Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response.
Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, Burks JK, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Zhao M, et al. Among authors: ma w. Nat Commun. 2024 Jan 2;15(1):180. doi: 10.1038/s41467-023-44239-2. Nat Commun. 2024. PMID: 38167338 Free PMC article.
Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA, Arslan E, Bartels M, Michikawa C, Lindemann A, Tomczak K, Yu W, Sandulache V, Ma W, Shen L, Wang J, Singh AK, Frederick MJ, Spencer ND, Kovacs J, Heffernan T, Symmans WF, Rai K, Myers JN. Osman AA, et al. Among authors: ma w. Clin Cancer Res. 2023 Apr 3;29(7):1344-1359. doi: 10.1158/1078-0432.CCR-22-2747. Clin Cancer Res. 2023. PMID: 36689560 Free PMC article.
TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro.
Singh SK, Wang Y, Habib A, Priyadarshini M, Kodavali CV, Chen A, Ma W, Wang J, Hameed NUF, Hu B, Fuller GN, Kulich SM, Amankulor N, Colen RR, Edwards LA, Zinn PO. Singh SK, et al. Among authors: ma w. Front Oncol. 2023 Oct 10;13:1279806. doi: 10.3389/fonc.2023.1279806. eCollection 2023. Front Oncol. 2023. PMID: 37881491 Free PMC article.
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Gordon MJ, et al. Among authors: ma w. Cancer. 2024 Mar 15;130(6):876-885. doi: 10.1002/cncr.35114. Epub 2023 Nov 20. Cancer. 2024. PMID: 37985359 Clinical Trial.
Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells.
Marques-Piubelli ML, Seervai RNH, Mudaliar KM, Ma W, Milton DR, Wang J, Muhlbauer A, Parra ER, Solis LM, Nagarajan P, Speiser J, Hudgens C, Cho WC, Aung PP, Patel A, Pacha O, Nelson KC, Tetzlaff MT, Amaria RN, Torres-Cabala CA, Prieto VG, Wistuba II, Curry JL. Marques-Piubelli ML, et al. Among authors: ma w. J Cutan Pathol. 2023 Jul;50(7):661-673. doi: 10.1111/cup.14442. Epub 2023 May 7. J Cutan Pathol. 2023. PMID: 37150813
12,648 results
You have reached the last available page of results. Please see the User Guide for more information.